Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL4896486 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223196 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Epiestriol SCHEMBL221084 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223226 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0772437-B9 | COMPOSITIONS FOR DELIVERY OF GENETIC MATERIAL | WYETH CORP (US) | 2008-05-14 | — | — | EP | claimed |
| EP-0772437-B1 | COMPOSITIONS FOR DELIVERY OF GENETIC MATERIAL | WYETH CORP (US) | 2006-06-07 | — | — | EP | claimed |
| US-5760214-A | NAPHTHACENE PIPERAZINE ESTROGEN STEROIDS FOR BONE DISORDERS | ISKRA INDUSTRY CO., LTD. (JP) | 1998-06-02 | — | — | US | claimed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | claimed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10610535-B2 | Diarylpropionitrile therapy for treatment of multiple sclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180161346-A1 | ESTRIOL THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-14 | — | — | US | disclosed |
| US-9452175-B2 | Pregnancy hormone combination for treatment of autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-27 | — | — | US | disclosed |
| EP-3045177-A1 | ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of The University of California (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160082017-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-24 | — | — | US | disclosed |
| US-6197755-B1 | ADMINISTERING UREA AND NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-03-06 | — | — | US | disclosed |
| US-5962428-A | IMMUNOLOGY RESPONSE | APOLLON, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5798348-A | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 1998-08-25 | — | — | US | disclosed |
| US-5739118-A | DNA AND SAPONIN | APOLLON, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0771817-A2 | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 1997-05-07 | — | — | EP | disclosed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610535-B2 | Diarylpropionitrile therapy for treatment of multiple sclerosis | ESR2, HSD17B11, GPER1 | ESR1 4/4885ESR2 1/4885LMNA 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.